regeneron glp-1 Announcing an in-licensing agreement for an investigational, novel dual GLP- 1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of Regeneron gains rights to Hansoh's

We strongly advise our readers to consult with a qualified healthcare professional before embarking on any weight loss program, prescription medication, or health-related protocol

Patients taking these drugs usually start on smaller doses and then work up to larger amounts, depending on their needs

To support your plan: Eat protein-rich meals Stay hydrated Prioritize sleep Add light daily movement Be consistent with dosing GLP-1 treatment may support weight management when combined with lifestyle habits and provider-guided medical support

5 Future directions The potential of GLP-1RAs as dual-action therapies, targeting both metabolic dysfunction and immune dysregulation, makes them particularly compelling candidates for early PsA, where intervention may alter disease trajectory

Some studies suggest fewer heart-related events in people with obesity who take GLP-1 drugs, possibly due to weight loss and other effects